The pro-coagulant protein Tissue Factor (TF, F3) is a powerful growth promoter in many tumors but its mechanism of action is not well understood. More generally, it is unknown whether hemostatic factors expressed on tumor cells influence TF-mediated effects on cancer progression. In this study, we investigated the influence of TF, endothelial cell protein C receptor (EPCR, PROCR) and protease activated receptor-1 (PAR1, F2R) on the growth of malignant pleural mesothelioma (MPM), using human MPM cells that lack or express TF, EPCR 
Introduction
It has been well recognized for many decades that tumors dramatically increase the risk for hemostatic abnormalities such as disseminated intravascular coagulation, pulmonary and venous thromboembolism (1) (2) (3) . Prior studies have also established that hemostatic factors play a major role in cancer biology, particularly in tumor dissemination and metastasis (4) (5) (6) . Tumor cell-associated tissue factor (TF) is known to contribute to tumor growth and progression either directly by TF-FVIIa or TF cytoplasmic tail-mediated cell signaling (7) (8) (9) , or indirectly through generation of thrombin that leads to activation of platelets, fibrin deposition, and activation of PAR1-mediated cell signaling (10) (11) (12) (13) .
Recent studies showed promotion of tumor growth by TF, independent of its role in coagulation (14) (15) (16) (17) . Selective inhibition of TF-FVIIa signaling using a specific monoclonal antibody that blocks TF signaling, but not TF-mediated coagulation, was shown to reduce breast tumor growth (14) . Blockade of PAR2 but not PAR1 cleavage by specific antibodies attenuated tumor growth. Consistent with the hypothesis that PAR2-mediated signaling contributes to tumor growth in breast cancer, mice lacking PAR2 but not PAR1, exhibited reduced tumor growth in a model of spontaneous mammary tumors (18) . Our recent studies on progression of malignant pleural mesothelioma (MPM) showed that MPM cells that express TF generated large tumors within the pleural cavity, and inhibition of tumor cell TF by overexpression of TFPI in tumor cells blocked tumor growth and invasion (19) . It is unknown at present whether TF-FVIIa-PAR2-mediated cell signaling contributes to growth of MPM as observed in breast cancer (14, 18) .
Recent studies from our laboratory and others have established that FVIIa, the protein that initiates the coagulation upon binding to TF, also binds to EPCR (20) (21) (22) . FVIIa binding to EPCR on the endothelium was shown to activate PAR1-mediated cell signaling providing barrier protective effect (23) . Disse et al. reported that EPCR promoted PAR1 and PAR2 cleavage by FXa in the ternary complex of TF-FVIIa-FXa (24) . Studies in cell model systems implicated that EPCR may promote tumor metastasis as EPCR-APC-mediated PAR1 signaling was shown to promote cancer cell migration, invasion, and angiogenesis (25, 26) . In vivo studies gave conflicting data as EPCR-APC signaling decreased lung metastasis in melanoma model by preventing tumor cell migration through enhancement of endothelial barrier function (27, 28) , whereas EPCR over expression increased metastasis in lung adenocarcinoma by promoting tumor cell survival (29) . To date, there is no information on whether EPCR directly influences tumor growth.
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In the present study, we show that MPM cells that express TF and PAR1 but not PAR2 generate large tumors in the thoracic cavity. Suppression of either TF or PAR1 reduces tumor growth in this model. However, overexpression of TF in less aggressive MPM cells that lack TF but express PAR1 failed to induce an aggressive phenotype. Interestingly, we found no EPCR expression in aggressive MPM cells whereas abundant EPCR expression was found in nonaggressive MPM cells. Introduction of EPCR expression to aggressive MPM cells by EPCR knock-in completely attenuated their tumorigenicity whereas the knock-down of EPCR expression in non-aggressive MPM cells engineered to overexpress TF markedly increased their tumorigenicity. The present study is the first to report that EPCR suppresses TF-driven tumor growth of mesothelioma. Characterization of these cells when they were first used in our tumorigenesis model showed an epitheloid phenotype in culture and retained classical MPM markers, confirming their MPM origin (29, 30) .
Generation of stable transfectants of MPM cells expressing/lacking TF, EPCR or PAR1
TF or PAR1 expression in REN MPM cells was selectively knocked-down by specific shRNA constructs cloned into pSilencer 2. 
Tissue factor activity
The procoagulant activity of TF on intact cell surface of wild-type and stable transfectants was measured in a factor X activation assay (31) .
Measurement of cytosolic Ca

2+ release
Fluorescence microscopy was used for measurement of cytosolic Ca 2+ release as described earlier (32) .
Orthotopic murine model of thoracic human MPM
One hundred µl of MPM cell suspension containing 1 x 10 6 cells were injected into the pleural cavity of nude mice as described earlier (30) with a few minor modifications. Mice were sacrificed between 28 and 30 days following tumor cell implantation, and tumor growth was evaluated as described earlier (30) .
Histology and immunohistochemistry
Tissues were processed for thin sectioning using standard procedures. Rehydrated tissue sections were processed for hematoxylin-eosin (H&E), elastin, collagen staining, or immunostaining for TF, EPCR, Ki67 or TUNEL staining.
Statistical analysis
Nonparametric statistical tests, Kruskal-Wallis or Mann-Whitney test, were used for determination of statistical significance. 
Results
Status of TF, EPCR, PAR1, PAR2, TM and TFPI expression levels in MPM cells
TF expression was markedly higher in REN cells compared to MS-1 and M9K cells ( Fig.   1A and B). TF expression was barely detectable in MS-1 and M9K cells. REN cells express very little EPCR whereas both MS-1 and M9K cells abundantly express EPCR, at levels found in endothelial cells (Fig. 1C) . As reported earlier (19) , REN cells lack TFPI expression whereas both MS-1 and M9K cells express TFPI (Fig. 1D) . TM expression was not detectable in REN cells and barely detectable in MS-1 cells, but abundant in M9K cells (Fig. 1E) . Western blot analysis revealed that all three MPM cell types express PAR1 whereas PAR2 expression was undetectable (Fig. 1F) . Consistent with the antigen data, a PAR1 but not PAR2 agonist peptide induced intracellular Ca 2+ release in REN cells (Fig. 1G) . A similar pattern of Ca 2+ release was observed in MS-1 and M9K cells, i.e., respond to PAR1, but not to PAR2 agonist peptide (data not shown).
REN MPM cells generate large invasive tumors and knock-down of TF reduces tumorigenicity of REN cells
As reported previously (30) , implantation of REN cells into the thoracic cavity of nude mice resulted in multiple large tumors (> 2 mm) within the thoracic cavity ( Fig. 2A) . The number of large tumors in each mouse varied from 6 to 18. Some of the tumors were approximately the size of the heart (Fig. 2B ). All tumors were limited to the thoracic cavity. These tumors were highly invasive and often penetrated deep into intercostal tissues on which they were attached ( Fig. 2C and 2D ). There was no evidence for metastasis as we found no tumors in distant (Fig. 3C) , and no significant differences were found between them in their tumor growth or burden ( Fig. 3D and Fig. 3E ). In contrast, mice injected with REN(-TF) cells developed fewer numbers of large tumors (Fig. 3C) . were selected for intrapleural injection (Fig. 6B) . Introduction of EPCR expression to REN cells markedly reduced the number of tumors formed in the thoracic cavity (Fig. 6C) , and the few tumors that were formed remained very small (Fig. 6F) . Thus, the total tumor volume and burden in mice injected with REN(+EPCR) cells was strikingly lower than that was observed with control REN(z) cells (Fig. 6D and 6E) . Although In vitro studies showed no measurable differences in cell proliferation between REN and REN(+EPCR) in the presence or absence of various ligands ( Supplementary Fig. 4 (Fig. 7F ). These MPM cell types formed not only large nodular tumors but they grew on lung pleura and diaphragm forming large coalescing tumors that tightly attached the bottom of lungs to diaphragm and esophagus, creating a large thick mass containing tumor cells, organs, and extracellular matrix (Fig. 7G, H) . In addition, small tumors on pericardial membrane and parietal pleura were clearly visible. Invasion of tumor cells into the intercostal space and along the ribs is also visible in all the mice injected with EPCR-knockdown MPM cells. The thoracic cavities of these mice were filled with bloody fluid (hemothorax).
7D-F). Mice injected with EPCR-knocked-down MS-1(+TF) and M9K(+TF) cells developed enormous tumor burden
Finally, some of the mice injected with EPCR knock-down of MS-1(+TF) or M9K(+TF) cells lost about as much as 25% body weight in the last week. Analysis of TM and/or TFPI levels in M9K(+TF) and MS-1(+TF) cells and their corresponding EPCR knocked-downs showed no significant differences in their expression levels ( Supplementary Fig. 5 ). In contrast to the increased tumor production obtained with EPCR knocked-down MS-1(+TF) and M9K(+TF) cells, EPCR knocked-down in parental MS-1 or M9K cells produced similar low tumorigenicity of parental cells (Fig. 7D-F) . Overall, our data clearly illustrate that EPCR suppresses TF-driven tumor growth in MPM.
In vitro cell proliferation studies showed no significant differences in cell growth pattern 
DISCUSSION
The increased expression of TF in tumor cells has been shown to associate with various aspects of tumor progression, including tumor growth, angiogenesis, invasion, and metastasis (7) (8) (9) . Tumor cell TF-induced activation of the coagulation pathway is believed to be primarily responsible for tumor cell dissemination and metastasis as down-stream coagulation activation results in thrombin-, platelet-, and fibrin-dependent pathways (6, 11, 12) . In contrast, a direct tumor cell TF-mediated cell signaling was shown to be responsible for tumor growth (14) .
Although regulators of coagulation, such as EPCR and TM, were also shown to influence metastatic potential (27, 28, 33) , their role in tumor growth was either unexplored or not completely understood (34) . In the present study, we used MPM cells that express or lack TF, (29) showed that APC/EPCR axis conferred a significant advantage to cell survival of lung adenocarcinoma cells, and this was responsible for robust prometastatic activity of lung adenocarcinoma. By extrapolation of these data, one would speculate that EPCR, as with TF, may promote tumor growth. However, the data presented in this study show clearly that EPCR, in fact, suppresses, tumor growth. This is an unexpected and novel finding, which runs contrary to the known functions of EPCR. At present, it is unknown whether tumor growth suppressive property of EPCR requires a specific pleural microenvironment or is specific to MPM cell types. Answering this requires extensive studies that involve deployment of other tumor growth models and tumor cell types, which are beyond the scope of the present work.
It is unknown, at present, whether the protective effect of EPCR on MPM tumor growth we observed is mediated by its anticoagulant function or cell signaling function. EPCR plays a key role in suppressing thrombin generation by promoting the activation of anticoagulant protein C to APC by thrombin-thrombomodulin complex. EPCR on tumor cells may simply inhibit the tumor growth by inhibiting thrombin generation, and thereby reducing thrombin-mediated PAR1-dependent tumor growth. However, it may be pertinent to note here that REN cells do not express TM, a cofactor needed for thrombin activation of EPCR bound protein C. Nonetheless, overexpression of EPCR in REN cells markedly reduced tumor growth. EPCR, in addition to supporting APC-mediated cell signaling, was shown to promote TF-FVIIa-FXa ternary complex signaling of PAR1 and PAR2 (24) . It is unlikely that EPCR suppresses MPM tumor growth through its interaction with TF-FVIIa-FXa ternary signaling complex since this would presumably promote, and not suppress, tumor growth because upregulation of TF-dependent signaling in tumor cells may in general lead to activation of pro-angiogenic and pro-tumor growth pathways (7) (8) (9) . Similar to TF, PAR1 signaling is also believed to contribute to cancer progression (13) .
However, at present, we can not exclude the possibility of PAR1 involvement in mediating the EPCR's protective effect as EPCR was shown to switch specificity of PAR1 signaling from damaging to protective signaling (47, 48) . For example, it had been shown that cleavage of PAR1 by thrombin initiates proinflammatory responses in endothelial cells in the absence of EPCR ligation whereas when EPCR was ligated by protein C, the cleavage of PAR1 by thrombin initiates antiinflammatory response (48) . Thus, it is conceivable that activation of (-TF) cells, and after 4 weeks mice were sacrificed, and tumor number (C), volume (D) and burden (E) were calculated (n = 10 to 13 mice/group, data from two experiments performed using two independent REN(-TF) stable transfectants, which gave similar results, were pooled).
Significance levels between the groups were determined by Kruskal-Wallis test (**P < 0.05) with
Dunn's post test to compare statistical significant differences between REN vs. REN(p) or REN(-TF). ns, not significant; **P < 0.01; ***P < 0.001. (F) Tumors sections were processed for histology by H&E staining or immunostaining with control IgG or anti-human TF IgG. 
